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Abstract: Bisphosphonates are the mainstay of treatment for postmenopausal women with 
osteoporosis. Despite numerous clinical trials documenting efﬁ  cacy, tolerability, and safety of 
bisphosphonate therapy, long-term persistence and adherence to these agents remains low. This 
has serious consequences for patients with osteoporosis in that medication non-compliance is 
associated with signiﬁ  cantly higher fracture risk. This review explores the unique physicochemical 
properties of bisphosphonates that allow more convenient intermittent dosing and whether less 
frequent dosing regimens improve compliance. Bisphosphonates are now available as oral 
drugs (taken daily, weekly, or monthly) or as intravenous preparations (given every 3 months 
or annually). The safety and efﬁ  cacy of these various preparations are reviewed and compared, 
with particular emphasis on the newest agent to be approved, once-monthly risedronate. In 
contrast to monthly oral ibandronate, risedronate is the ﬁ  rst and only monthly oral bisphospho-
nate to offer both vertebral and non-vertebral fracture reduction, based upon non-inferiority 
trials. Whether the greater convenience of this monthly oral bisphosphonate will translate into 
improved compliance and lower fracture risk is yet to be determined.
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Introduction
Osteoporosis is characterized by a reduction in bone density and strength, and an 
increase in risk of fractures with minimal trauma. It is estimated that in 2010, 12 million 
individuals in the United States will have osteoporosis and 40 million more will have 
low bone density.1 Worldwide, 200 million people have osteoporosis, and as the 
population ages, these numbers will continue to rise.2
Fractures associated with osteoporosis have a major impact on quality of life, 
mortality, and health care costs. Over 2 million osteoporosis-related fractures occurred 
in 2005 in the United States.3 Spine and hip fractures are particularly debilitating and 
costly. Within the ﬁ  rst year after a hip fracture, mortality is increased 10% to 20% 
and long-term disability is common. Half of those who sustain a hip fracture are no 
longer able to walk independently, and up to one-third remain in a long-term care 
facility.4 Vertebral fractures also result in excess mortality with the effect persisting 
beyond 1 year after the event.4 Kyphosis and height loss caused by vertebral fractures 
contribute to reduced activity levels and cardiopulmonary morbidity. The risk of 
subsequent fractures at any site after a vertebral fracture is dramatically increased, 
with hip fractures 2 to 3 times more frequent.5 The costs associated with acute treat-
ment, rehabilitation, and nursing home facilities following osteoporotic fractures are 
approximately US$20 billion per year in the US.3,4 Hip fractures account for 72% of 
the economic burden though only comprising 14% of osteoporotic fractures.3
A variety of pharmacologic agents are available for the prevention and treatment 
of osteoporosis, including bisphosphonates (BPs), selective estrogen receptor modula-
tors, calcitonin, and teriparatide. Estrogen/progestin therapy is also effective against International Journal of Women’s Health 2009:1 2
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osteoporosis but its use is limited to women with menopausal 
symptoms. Because of signiﬁ  cant efﬁ  cacy against fractures 
and good tolerability, bisphosphonates have become the 
cornerstone of therapy for osteoporosis.
Unique pharmacokinetics 
of bisphosphonates
Chemically, all bisphosphonates contain a phosphate-carbon-
phosphate (P-C-P) bond that is resistant to biological degra-
dation.6 Various substitutions at positions R1 and R2 on the 
carbon atom deﬁ  ne the speciﬁ  c pharmacologic properties 
and mechanisms of action of the different bisphosphonates 
(see Figure 1). The unique chemical structure of the BPs acts 
as a ‘bone hook’, allowing rapid and widespread distribution 
of BPs onto bone mineral surfaces.7 The speciﬁ  c structure 
of the R2 side chain determines the biological activity and 
antiresorptive potency of the BP molecule. Bisphospho-
nates containing nitrogen moieties at the R2 site, including 
risedronate, ibandronate, alendronate and zoledronate, are 
much more potent as antiresorptive agents compared with 
non-nitrogen-containing BPs, such as etidronate.8
As a class, BPs are very poorly absorbed from the 
intestine with 50% of the absorbed dose taken up by the 
skeleton and the rest excreted in the urine.6 Though cleared 
from the plasma within 6 to 10 hours after administration,9 
the portion bound to bone is slowly released back into the 
circulation over months or years.10 Bisphosphonates are 
distributed into two bone compartments, one at the bone 
surface, where they exert their action, and the second, 
deeper within the bone matrix, where they remain bio-
logically inert until released by later bone resorption.6 The 
uptake and retention of bisphosphonates within the skeleton 
depend upon many factors including renal function, rate 
of bone turnover, number of available binding sites, and 
speciﬁ  c binding properties and potencies of the different 
bisphosphonates.6
The activity of bisphosphonates is dependent on the 
continuous bone-remodeling cycle that “renews” the skel-
eton throughout life. Quiescent cells on the surface of bone 
are “activated” to begin bone remodeling at a speciﬁ  c area 
of the skeleton. Over a period of 2 weeks, activated osteo-
clasts remove old or damaged bone, leaving microscropic 
pits known as “lacunae” on the bone surface. As osteoclasts 
regress, bone-forming osteoblasts are recruited to secrete new 
osteoid (unmineralized bone) into the lacunae. This new bone 
is laid down and mineralized over the next 3 to 4 months, 
completing the bone remodeling cycle.11
Potent nitrogen-containing bisphosphonates directly inhibit 
osteoclastic bone resorption resulting in a net gain in bone mass 
as the resorption pits are ﬁ  lled in with new bone. They also 
cause a decrease in bone turnover and a reduction in the rate of 
new fractures.12 The process begins as bisphosphonates selec-
tively bind to bone mineral at active sites of bone remodeling. 
During osteoclastic bone resorption, osteoclasts “ingest” the BP 
which induces a cascade of intracellular changes causing apop-
tosis (cellular death) of the osteoclasts.6 As osteoclastic bone 
resorption slows down, the osteoblasts have more time to ﬁ  ll in 
empty lacunae and to restore bone structure and bone strength. 
Ultimately, though, osteoblastic bone formation also slows down 
as the two processes (resorption and formation) are “coupled.” 
As measured by biochemical markers of bone formation and 
bone resorption, the decrease in bone formation is slower and 
lags behind the decrease in bone resorption by several months. 
With continued BP administration, both bone resorption and 
bone formation reach new, lower steady states.13
Since BPs have very high afﬁ  nity for bone tissue and long 
half-lives, they can remain active at the surface of bone for 
extended periods of time between doses.12,14 For this reason, 
weekly administration of BPs may be categorized as continuous 
rather than truly intermittent therapy.9 The efﬁ  cacy of longer 
dosing intervals such as monthly or yearly administration of BPs, 
suggests that the inert drug buried beneath the bone surface must 
be recycled and reactivated by osteoclastic bone resorption.15
Skeletal retention varies between BPs due to differences 
in binding properties so that not all drugs in this class may 
be able to be dosed at long, intermittent intervals.6 The dif-
ference in binding afﬁ  nities is mainly due to differences in 
the R2 side chain with a rank order of (from highest binding 
afﬁ  nity to lowest) as follows:16
zoledronic acid  alendronate  ibandronate









Figure 1 Structure of bisphosphonates: phosphate-carbon-phosphate (P-C-P) 
backbone, hydroxyl (-OH) groups, and substitutions at R1 and R2. Chemical group at 
R1 along with 2 phosphonate groups form the “bone hook” that is essential for binding 
to bone mineral; the three dimensional structure of the chemical group at R2 is critical 
for the biologic activity and antiresorptive potency of the molecule.International Journal of Women’s Health 2009:1 3
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The binding afﬁ  nities of bisphosphonates for bone affect 
many important biological properties including uptake and 
retention in the skeleton, diffusion of the drug within bone, 
release of adsorbed drug from bone, potential recycling of the 
drug back onto bone surfaces and effects on mineral dynamics 
and cellular function within bone.7 The ability of the BP to 
attach to bone mineral also contributes to its potency and 
duration of action. Higher afﬁ  nity BPs, such as zoledronic 
acid, ibandronate and alendronate have more rapid uptakes, 
lower detachment rates, higher re-attachment rates and lower 
diffusion rates in the bone compared to risedronate.16
Compliance and importance 
of less frequent drug dosing
Despite proven efﬁ  cacy, good tolerability, and safety, patient 
compliance with BPs for osteoporosis remains poor. Reasons 
for suboptimal compliance with all osteoporosis therapies 
include the cost of medications, concerns about drug-related 
side effects, lack of understanding or motivation on the part of 
the patient, difﬁ  culty in treating an asymptomatic disease, and 
inconvenience.17–19 A number of side effects associated with 
oral bisphosphonates may also limit optimal compliance. 
These include gastritis, esophagitis, reﬂ  ux, ulcers, abdominal 
discomfort, and musculoskeletal pains. In addition to side 
effects, convenience or lack thereof may play a particularly 
important role in adherence to oral bisphosphonate therapy.18 
The special dosing requirements for oral bisphosphonates 
include the need to take the drugs after an overnight fast, 
on a completely empty stomach, with 6 to 8 ounces (200 to 
250 mL) of water, in an upright position, with no other 
food, pills, or beverages for at least 30 minutes. The drugs 
are contraindicated in patients with swallowing problems or 
difﬁ  culties remaining upright for at least 30 to 60 minutes. 
These strict requirements, necessary for the optimal absorp-
tion, effectiveness, and tolerability of these drugs, may be 
inconvenient and in some cases, impossible to meet.
A recent review of 14 different international pharmacy 
databases found that a high percentage of women with osteo-
porosis are not optimally compliant or persistent with their 
medication regimen.20 In a study of 8822 new users of bisphos-
phonates, only 58% were compliant after 1 year.21 Those on 
weekly oral bisphosphonates had consistently higher rates of 
compliance and persistence than those on daily regimens but 
still fell well below acceptable levels.20 An analysis of a broad 
US retail pharmacy database with over 211,000 patients on 
oral bisphosphonates, found that adherence to therapy over 
a 12-month period was signiﬁ  cantly higher among patients 
on weekly versus daily therapy.22 However, only one-third 
of those receiving daily bisphosphonates and 45% of those 
on weekly bisphosphonates achieved adequate adherence 
levels.22 In general, patients on weekly oral bisphosphonate 
regimens are 1.5 times more likely to persist with therapy 
compared to those on daily regimens.20,21,23
If weekly therapy leads to better medication compliance 
than daily, would monthly oral therapy achieve even better 
results? In a prospective cross-over trial, 342 postmeno-
pausal women with osteoporosis were randomized to either 
once-monthly ibandronate 150 mg followed by once-weekly 
alendronate 70 mg, or the opposite sequence, for a total of 
6 months. Overall, 66% of women preferred the once-monthly 
regimen over the once-weekly regimen, mainly due to conve-
nience and “ease of following a treatment regimen for a long 
time.”24 When 248 women on weekly bisphosphonate therapy 
were switched to monthly ibandronate for 6 months, 95% 
stated a preference for the convenience of the monthly drug.25 
However, in an Internet-based survey of nearly 1000 post-
menopausal women diagnosed with or at risk for osteopo-
rosis, drug effectiveness against fractures was ranked as the 
most important attribute inﬂ  uencing drug preference while 
dosing frequency and dosing procedure were ranked much 
lower in importance.26 Another online survey of 617 current 
bisphosphonate users found that patients preferred weekly 
therapies (risedronate or alendronate) over monthly therapy 
(ibandronate) by a very wide margin (82% vs 18%, respec-
tively) when informed that the weekly therapies had broader 
anti-fracture efﬁ  cacy.27 Almost identical results were found in 
a European study using face-to-face or telephone interviews 
with similar prompting.28 The studies by Gold and Keen were 
both sponsored by Procter and Gamble Pharmaceuticals and 
Sanoﬁ  -Aventis, the manufacturers of risedronate.
Gold et al found that among 240,000 patients in a phar-
macy database receiving either weekly risedronate or monthly 
ibandronate, rates of persistence, adherence, and compliance 
were signiﬁ  cantly higher with the weekly therapy.27 The 
authors speculate that very infrequent dosing may result in 
skipping doses. They also suggest that earlier studies showing 
a preference for monthly dosing were biased by the presence 
of patient support programs for users of the monthly drug.27 
In a separate analysis of 166,000 women aged 50 years or 
older who were newly prescribed weekly alendronate or 
monthly ibandronate, ibandronate users were 10% more 
likely to discontinue therapy within the ﬁ  rst year compared 
with those prescribed alendronate.29 Ibandronate requires a 
higher co-pay which is offset by discount vouchers for the 
ﬁ  rst pill. After taking the ﬁ  rst month’s pill, 54% of patients 
on ibandronate failed to renew the prescription compared International Journal of Women’s Health 2009:1 4
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with 46% of alendronate users.29 Once this initial effect was 
eliminated, however, there were very few differences in 
persistence between the groups by the end of one year.29
There appear to be many determinants of patient per-
sistence with medication. Weiss et al argue that dosing fre-
quency is clearly not the only driver and may not even be an 
important driver of persistence with oral bisphosphonates.29 
Other important factors such as experience with side effects, 
practical difﬁ  culties with the dosing regimen, out of pocket 
costs, skepticism about drug efﬁ  cacy or treatment beneﬁ  t, 
lack of motivation, and concern about both short-term and 
long-term drug safety may be of far greater importance.29
Consequences of poor compliance 
and adherence
Randomized clinical trials are critical for determining the 
safety and efﬁ  cacy of drugs for osteoporosis. Unfortunately, 
they are not the best measures of “real world” conditions, 
particularly with respect to patient adherence to therapy. 
Even the most potent therapies for osteoporosis may “fail” 
if patients do not take medications properly or consistently 
over prolonged periods of time. Lack of adherence to oral 
bisphosphonate therapy has been associated with inadequate 
suppression of bone turnover markers as well as less than 
optimal gains in bone mineral density.30–32 Most importantly, 
poor adherence has been linked to higher fracture rates.
Bisphosphonate users with inconsistent adherence had 
33% higher 10-year fracture rates than consistent users.32 In 
a retrospective analysis of a pharmacy and medical claims 
database comprising over 35,000 women on oral bisphospho-
nates, compliant women had 21% fewer fractures relative to 
non-compliant women (p  0.001).33 Women who persisted 
with bisphosphonate therapy over 24 months had reductions 
of 40%, 29%, and 45% in vertebral, non-vertebral, and hip 
fractures, respectively, compared to non-persistent women 
(p  0.001).33 Overall, less than half of the women in this 
population were compliant with bisphosphonate therapy and 
only 1 in 6 persisted with therapy for 24 months.33
A variety of international studies have found similar 
results. Among 44,000 British men and women on oral 
bisphosphonates, hip/femur fractures were reduced 22% in 
those who persisted with therapy for 1 year or more.34 In 
a population from the Netherlands, patients who persisted 
with therapy for 2 years had 32% fewer fractures than those 
who stopped therapy before 2 years.35 Among 8822 new 
female users of daily or weekly oral bisphosphonates in the 
Netherlands, compliance less than 80% was associated with 
a 40% increased risk of osteoporotic fracture compared with 
those with higher compliance rates.36 Fracture risk increased 
steadily as the compliance rate decreased. Those with the very 
lowest compliance had an 80% higher risk of fracture than 
those with the highest compliance.36 Finally, in a nested case 
control study from a large database in Quebec, women who 
sustained non-vertebral fractures while taking oral bisphos-
phonates for osteoporosis (cases) were matched with up to 
20 age-matched women (controls) from the same database 
who were on bisphosphonates but did not fracture. Compared 
to controls, cases were frailer, had more risk factors for frac-
ture, and were less compliant with bisphosphonate therapy. 
Even after controlling for confounding variables, lower 
compliance among the cases was associated with a 27% 
increased risk of fracture compared with controls.37
Clinical trials with oral 
bisphosphonates
A number of randomized placebo-controlled prospective 
fracture trials supported the efﬁ  cacy of once-daily oral BPs 
including alendronate, risedronate, and ibandronate in the treat-
ment of postmenopausal osteoporosis.38–44 All of these drugs, 
when given once per day, signiﬁ  cantly reduced the relative risk 
(RR) of vertebral fractures by 41% to 62%. In addition, daily 
oral alendronate reduced the RR of non-vertebral fractures by 
47% (p = 0.021) in a group of women with low bone mineral 
density (BMD) (lumbar spine T-score of −2.0 or lower).45 In 
a posthoc analysis of 4 clinical trials involving 620 postmeno-
pausal women with osteopenia (T-score at the femoral neck 
between −1 and −2.5), 5 mg daily oral risedronate reduced the 
RR of all fragility fractures by 73% compared with placebo 
(p = 0.023).45 These results suggest that both daily alendronate 
and risedronate are effective in reducing fractures in post-
menopausal women with osteopenia as well as osteoporosis. 
With respect to hip fractures, daily oral risedronate reduced 
the RR of hip fracture by 30% in 5445 elderly women with 
osteoporosis at the femoral neck.46 However, in this same 
study, oral daily risedronate did not reduce hip fractures in 
elderly women who had clinical risk factors for hip fracture 
but were not necessarily osteoporotic.46
Ibandronate given daily (2.5 mg) or intermittently (20 mg 
every other day for 12 doses every three months) reduced 
vertebral fractures signiﬁ  cantly when compared to placebo.42 
Neither treatment group showed a signiﬁ  cant decrease in 
non-vertebral fractures, except for a subset of patients with 
very low BMD at the femoral neck (T-score  −3).42 The 
ibandronate trials were the ﬁ  rst to show that truly intermit-
tent oral BP regimens could reduce fractures as well as daily 
regimens.International Journal of Women’s Health 2009:1 5
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Decreasing the frequency or number of doses of a drug is 
a common strategy for enhancing adherence for all medica-
tions.47 Among the oral drugs, weekly dosing of alendronate 
and risedronate, monthly ibandronate, and, most recently, 
risedronate given on two consecutive days a month or once 
per month, have all been approved for use based on non-
inferiority trials. Non-inferiority trials with new dosing 
regimens have used BMD, not incidence of fracture, as the 
primary endpoint. Because BMD is inversely correlated 
with fracture risk, the FDA considers it to be an acceptable 
surrogate when approving new dosing regimens.
Until recently, ibandronate had been the only oral 
bisphosphonate offered in a monthly form. A randomized 
non-inferiority trial (MOBILE trial) found that after one 
year, treatment with monthly ibandronate, when compared 
to daily dosing, improved BMD similarly at both lumbar 
spine and hip in postmenopausal women with osteoporosis. 
Those who received 150 mg monthly had superior gains in 
lumbar spine BMD compared with 2.5 mg daily (4.9% for 
150 mg monthly vs 3.9% in 2.5 mg daily).48
Intermittent oral risedronate therapy
Risedronate has also been studied as an intermittent therapy. 
Weekly dosing of risedronate was studied in a 2-year 
randomized clinical trial of postmenopausal osteoporotic 
women.49 Brown et al found that there was no signiﬁ  cant 
difference in lumbar spine (LS) BMD improvement between 
risedronate 5 mg daily, 35 mg weekly, or 50 mg weekly. 
The three doses had similar effects on secondary endpoints 
including total hip, femoral neck, and trochanter BMD, bone 
turnover marker (BTM) levels, and incidence of vertebral 
fractures. Adverse side effect proﬁ  les were also similar 
among the three treatment groups.49 These results led to 
approval of 35 mg weekly risedronate in 2002.
A 6-month pilot study compared 5 mg daily risedronate 
with 50 mg on 3 consecutive days a month.50 One-hundred-
ﬁ  fty women aged 65 to 80 with low BMD (T-scores  −2) 
were randomized to received 5 mg daily, 50 mg for 3 con-
secutive days a month, or 15 mg daily loading dose for a 
month followed by 50 mg on 3 consecutive days a month.50 
Serum markers of bone turnover including N-telopeptide 
(NTX), C-telopeptide (CTX), and serum bone speciﬁ  c alka-
line phosphatase (BAP) served as evidence for efﬁ  cacy over 
the 6-month period, with NTX serving as a primary endpoint. 
BMD was measured at baseline and after 6 months.
Levels of NTX, CTX, and BAP were reduced signiﬁ  -
cantly from baseline in all three groups and there was no 
significant difference between the groups at 6 months. 
Mean percent changes from baseline at LS BMD at month 6 
were similar among treatment groups as well as were adverse 
events. While this study showed promise in the efﬁ  cacy 
and safety of risedronate monthly, the small sample size 
and brief length of follow-up were not powered to conﬁ  rm 
non-inferiority.50
Recently, two well-powered international, multicenter, 
randomized, double blind trials have investigated the efﬁ  cacy 
and safety of intermittent risedronate. In one, postmenopausal 
women with osteoporosis were randomized to risedronate 
5 mg daily (n = 613) or 75 mg on 2 consecutive days a month 
(2CDM) (n = 616) for 2 years.51 The primary endpoint was 
percent change from baseline in LS BMD at 12 months 
of treatment. Mean percent change in LS BMD was 
3.4% ± 0.16% in the 75 mg 2CDM group, and 3.6% ± 0.15% 
in the 5 mg daily group. These both represented signiﬁ  cant 
increases in BMD, without signiﬁ  cant difference between 
the two regimens, thereby conﬁ  rming non-inferiority of the 
75 mg 2CDM regimen.
Secondary efﬁ  cacy was measured with mean percent 
change from baseline in LS, total hip, trochanter, and femoral 
neck BMD, and BTMs. Both groups had a signiﬁ  cant effect 
on these measures, without a signiﬁ  cant difference between 
the two groups. Incidence of new vertebral fractures was 
also assessed, by comparing radiographs at baseline and 
at 12 months. There was no difference between groups in 
new vertebral fractures (6 fractures in the 75 mg 2CDM and 
7 fractures in the 5 mg daily).51
There were no clinically relevant differences in safety 
and tolerability between the two groups and a similar number 
of subjects in each group experienced treatment-emergent 
adverse events (TEAEs). The most common TEAEs in both 
groups (ie, 10% of subjects) were arthralgias and back pain. 
Withdrawal occurred in 9% of subjects in both groups, and 
was most commonly related to gastrointestinal symptoms. 
Acute phase reactions (fever or ﬂ  u-like illness within the ﬁ  rst 
5 days of treatment) were experienced in a small, but higher, 
number of patients in the 75 mg on 2CDM group (4 subjects) 
than in the 5 mg daily group (0 subjects). The authors of the 
study concluded that 75 mg of risedronate on 2CDM was at 
least as effective and safe as 5 mg daily.51
In a 2nd randomized trial, Delmas et al found that 150 mg 
of risedronate monthly had similar efﬁ  cacy and tolerability as 
5 mg daily after the ﬁ  rst year of a 2-year study.52 Postmeno-
pausal women with osteoporosis were randomized to receive 
150 mg of risedronate as one dose a month (with placebo 
pills for the rest of the month) (n = 650), or 5 mg daily (n = 642). 
The primary endpoint was the mean percent change from International Journal of Women’s Health 2009:1 6
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baseline in LS BMD after one year. The mean percent change 
in LS BMD was 3.4% (95% CI 3.30%–3.82%) in the 5 mg 
daily group and 3.5% (95% CI 3.15%–3.93%) in the 150 mg 
monthly group; a difference of −0.1% (95% CI −0.5%–0.27%) 
between groups. These numbers represented a signiﬁ  cant 
improvement in LS BMD in both groups, without difference in 
efﬁ  cacy between groups, and satisﬁ  ed pre-determined criteria 
for non-inferiority.52
Change from baseline BMD at the total proximal femur, 
femoral neck, and trochanter were also measured and found to 
be signiﬁ  cantly increased in both groups, with no signiﬁ  cant 
difference between groups at any point in time. Bone turnover 
markers (NTX, CTX, BAP) were decreased signiﬁ  cantly and 
to similar degrees in both groups at endpoint. The incidence 
of vertebral fractures was measured by comparing radio-
graphs at baseline to radiographs after the ﬁ  rst 12 months 
of treatment and was found to be equal: 8 subjects in each 
group had a new vertebral fracture.52
Safety and tolerability were considered to be comparable 
between the two groups as well. Adverse events considered to 
be of special interest for bisphosphonates (including clinical 
vertebral and non-vertebral fractures, upper gastrointestinal 
AEs, and musculoskeletal events) were reported at similar 
frequency in both groups. Diarrhea and inﬂ  uenza were the 
only AEs reported more frequently in the monthly group, 
with 5 patients withdrawing due to diarrhea. Most cases of 
inﬂ  uenza occurred more than 90 days after treatment and 
all were considered mild or moderate in severity. No sub-
jects withdrew as a result. The incidence of potential acute 
phase reactions (inﬂ  uenza or ﬂ  u-like illness and/or pyrexia 
within 3 days of start of treatment) was slightly higher in the 
monthly group (1.4% in the monthly group and 0.2% in the 
daily group), but only one event, in the monthly group, was 
considered severe. Furthermore, only one subject withdrew 
as a result of a reaction.52
Intermittent intravenous therapy 
for osteoporosis
Despite efforts to make oral BPs more convenient by moving 
to intermittent, less frequent dosing, a number of patients 
are still unable to tolerate these drugs. As noted earlier, the 
most common side effects are gastrointestinal including 
gastritis, esophagitis, reﬂ  ux, abdominal pain and ulcers. The 
oral BPs may be poorly absorbed and ineffective in patients 
with intestinal malabsorption syndromes. The drugs are 
contraindicated in patients with swallowing problems or 
difﬁ  culties remaining upright for at least 30 to 60 minutes. 
Less frequent dosing does not eliminate the need to take 
the oral BPs properly, as outlined above, and may result in 
poor compliance and persistence, particularly among elderly 
patients with complicated medication regimens or cognitive 
difﬁ  culties.
The intravenous BPs eliminate a number of the drawbacks 
of oral BPs. Currently, two intravenous preparations are 
FDA-approved for osteoporosis in the United States. These 
include ibandronate 3 mg given as an intravenous (iv) 
injection over 15 to 30 seconds once every 3 months53–55 and 
zoledronic acid 5 mg given as a once-yearly iv infusion over 
15 to 20 minutes.56,57 The ibandronate trials did not include 
fracture endpoints but simply looked at changes in BMD and 
bone resorption markers. In contrast, both zoledronic acid 
trials had vertebral and nonvertebral fracture endpoints. In 
the 3-year randomized, prospective placebo-controlled study 
of postmenopausal women with osteoporosis by Black et al 
an annual infusion of 5 mg zoledronic acid signiﬁ  cantly 
reduced morphometric vertebral, clinical vertebral, hip and 
non-vertebral fractures by 70%, 77%, 41%, and 25%, respec-
tively.56 The HORIZON study conducted by Lyles et al was 
the ﬁ  rst clinical trial to study secondary fracture prevention 
and other outcomes in patients with recent hip fractures.57 
Only 41% of this patient population had osteoporosis accord-
ing to BMD measurements at the femoral neck while the rest 
had normal or osteopenic BMD at the hip. In this high-risk 
population, the authors reported a signiﬁ  cant 35% reduction 
in all clinical fractures and a 28% risk reduction in all-cause 
mortality in the patients who received zoledronic acid versus 
placebo.57
Comparisons between different 
bisphosphonates
There are no head-to-head antifracture studies comparing 
the various oral and intravenous bisphosphonates on the 
market. Without such studies, current evidence does not 
support a clear distinction in fracture reduction among the 
different agents. Surrogate markers, such as BMD changes 
and suppression of biochemical markers of bone turnover, 
have been compared between alendronate and risedronate 
users in a randomized double blind clinical trial (the FACT 
study).58 In this 12-month study of 833 postmenopausal 
women with osteoporosis, 70 mg of weekly alendronate 
resulted in signiﬁ  cantly greater BMD increases at all sites 
and signiﬁ  cantly lower markers of bone turnover compared 
to 35 mg of weekly risedronate.58 A 1-year extension of this 
study continued to show that alendronate “outperformed” 
risedronate on every measure including BMD increases, 
suppression of bone turnover markers, and number of International Journal of Women’s Health 2009:1 7
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responders.59 Adverse events did not differ between the 
two groups.
The differences in antiresorptive efﬁ  cacy between alen-
dronate and risedronate may be related to the greater afﬁ  nity 
of alendronate for hydroxyapatite and its longer retention in 
bone.16 These properties, though beneﬁ  cial in some respects, 
have raised concerns about potential over-suppression of 
normal bone activity in long-term alendronate users.60 Several 
case reports have linked chronic use of alendronate, for 
5 or more years, with sudden, low-energy, subtrochanteric 
fractures.61–63 However, a recent report using a cross-sectional 
and matched cohort national database found no increase in 
these atypical femur fractures among alendronate users.64 
Another concern is the relationship between bisphosphonates 
and osteonecrosis of the jaw (ONJ). Reports of ONJ occurring 
in cancer patients treated with iv bisphosphonates led to ques-
tions about the safety of oral bisphosphonates in treatment 
of osteoporosis. A literature review found that ONJ occurred 
rarely (23 cases) in patients taking oral bisphosphonates for 
osteoporosis, especially considering that millions of patients 
have been prescribed bisphosphonates for this purpose.65 
Furthermore, many cases had a history of invasive dental 
treatment with dental trauma at the site of ONJ. In the two 
largest trials of intravenous zoledronic acid for treatment of 
osteoporosis,56,57 there was no increased risk of ONJ in those 
receiving the bisphosphonate for up to 3 years. An extensive 
review of ONJ is beyond the scope of this paper.
Two short-term studies have compared annual intrave-
nous zoledronic acid with weekly oral alendronate.66,67 In a 
24-week trial comparing a single-infusion of zoledronic acid 
with weekly oral alendronate in postmenopausal women with 
osteoporosis, zoledronic acid caused a greater and more rapid 
reduction in bone turnover markers compared with weekly 
alendronate.66 However, acute phase reactions consisting of 
ﬂ  u-like symptoms and fever within 3 days of the infusion 
were seen much more frequently with zoledronic acid com-
pared with alendronate (18.8% vs 5.1%). Despite this, most 
patients expressed a preference for annual iv therapy (66.4%) 
compared with weekly oral therapy (19.7%).66
A second head-to-head comparison trial between annual iv 
versus weekly oral BP therapy was conducted by McClung 
et al67 It was a 12-month trial involving postmenopausal 
women with osteoporosis who had received at least 1 year 
of alendronate, prior to randomization. Participants were 
randomized to receive either one 5-mg zoledronic acid 
infusion or 70 mg of weekly alendronate. The primary out-
come was the percent change from baseline in lumbar spine 
BMD at the end of one year. Zoledronic acid maintained the 
therapeutic effect of prior alendronate. Moreover, the annual 
iv infusion was preferred by 79% of the patients at the end 
of the study. Adverse events were mild and similar between 
the groups. Interestingly, none of the patients who switched 
from alendronate to zoledronic acid experienced acute phase 
reactions suggesting that longer exposure to BPs causes a 
waning of this side effect.
Conclusion: monthly risedronate 
for osteoporosis
Bisphosphonates have become the mainstay of treatment in 
most patients with postmenopausal osteoporosis. By reducing 
excessive osteoclast activity, BPs are able to restore the rate 
of bone turnover to premenopausal levels, thereby preventing 
further deterioration of bone quality in patients with acceler-
ated bone loss.7 Oral alendronate, risedronate and ibandronate 
have all been shown to reduce the risk of vertebral fractures, 
but only alendronate and risedonate have been documented 
to reduce non-vertebral and hip fractures.
There are many causes for nonresponse to anti-osteoporosis 
therapy including co-morbid conditions, malabsorption, 
calcium and vitamin D deﬁ  ciency, and poor compliance 
with therapy.68 Suboptimal compliance with daily and even 
weekly oral BPs has been associated with higher fracture 
rates. In an effort to improve compliance and persistence 
with therapy, less frequent oral and iv dosing regimens have 
been developed. Monthly oral risedronate offers patients 
the convenience and ease of monthly self-administration. 
In contrast to monthly oral ibandronate, risedronate is the 
ﬁ  rst and only monthly oral BP to offer both vertebral and 
non-vertebral fracture reduction (though this is based on non-
inferiority studies, not actual fracture trials with the monthly 
preparation). There are no head-to-head studies comparing 
efﬁ  cacy, tolerability, or patient preferences between oral 
monthly risedronate and once-yearly iv zoledronic acid, but 
studies comparing weekly alendronate and annual iv zole-
dronic acid suggest that patients may prefer the once per year 
iv infusion over a weekly oral therapy. Whether this same 
preference applies to monthly oral therapy remains unclear. 
In the end, other factors such as cost, insurance coverage, 
physician and patient preferences, familiarity with the iv drug 
administration,7 and concerns about safety of the iv infusion, 
may be the most important issues determining the place of 
monthly risedronate in the armamentarium of osteoporosis 
drug therapies.
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